Connect to other sites within the UBM Medica Network
Monoclonal Antibody Effective in Refractory Myeloma
Daratumumab, a monoclonal antibody that targets CD38, was safe and effective in patients with heavily pretreated and refractory multiple myeloma.
Continuous Therapy Delayed Progression in Newly Diagnosed Myeloma
Continuous therapy resulted in delays in first and second progression compared with fixed-duration therapy in patients with newly diagnosed multiple myeloma.
Staging System Revised for Multiple Myeloma
The International Myeloma Working Group has published a revised International Staging System for multiple myeloma that incorporates chromosomal abnormalities.
Engineered T Cells Elicit Clinical Response in Advanced Myeloma
Eighty percent of patients with advanced multiple myeloma had a clinical response to a new T cell–receptor therapy that used T cells to target cells expressing NY-ESO-1.
Carfilzomib Gets Expanded FDA Approval for Multiple Myeloma
The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.
Regimen Yields Deep Responses in High-Risk Smoldering Myeloma
Treatment with carfilzomib plus lenalidomide and dexamethasone resulted in high rates of minimal residual disease negativity in patients with newly diagnosed or smoldering high-risk multiple myeloma.
Doublets Match Triplet Regimens in Transplant-Ineligible Myeloma
Use of a VD regimen alone to treat patients with transplant-ineligible multiple myeloma was not inferior to VTD or VMP regimens, according to the UPFRONT trial.
By clicking Accept, you agree to become a member of the UBM Medica Community.